What is protein sequencing?
Protein sequencing is the process of determining the order of amino acids that make up a protein. Reading proteins directly, rather than inferring them from genes, reveals how biology actually functions, including modifications that genes alone can't predict.
What is Protein Sequencing by Expansion (ProSE™)?
ProSE™ is Glyphic's single-molecule, massively parallel protein sequencing platform. Peptides are functionalized with an initiating linker, then each amino acid is sequentially expanded and uniformly spaced in its original order, enabling the protein to be read one molecule at a time.
How is ProSE different from traditional methods like mass spectrometry?
Traditional approaches have built-in blind spots: antibody-based methods like ELISA only detect proteins you already have a reagent for, and mass spectrometry typically matches signals against databases of known proteins. Both are biased toward what's already been characterized. ProSE™ reads proteins de novo, one molecule at a time, with no reference database required. That makes it unbiased and able to illuminate the “dark proteome”: the vast space of proteins, isoforms, and modifications that today's methods simply can't see.
Can ProSE detect post-translational modifications (PTMs)?
Yes. ProSE™ is designed to read all 20 amino acids and post-translational modifications, which are often central to disease biology and therapeutic development.
Why does single-molecule protein sequencing matter?
Reading the proteome at single-molecule resolution can accelerate the development of novel therapeutics and diagnostics and deepen our understanding of biology.
What is Glyphic Biotechnologies?
Glyphic Biotechnologies is a Berkeley, California biotechnology company, founded in 2021, developing next-generation protein sequencing technology (ProSE™).